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Original article
of DED pathology. Tear hyperosmolarity causes apoptosis of 
cells of the conjunctiva and cornea while also triggering in-
flammatory cascades that contribute to further cell apoptosis 
and altered mucin production. This in turn exacerbates tear 
film instability, leading to more tear hyperosmolarity (3).
Individuals with DED experience eye symptoms including 
irritation, pain, dryness, foreign body sensation, and visual 
disturbance (1). The severe form of the disease is character-
ized by persistent and recurrent symptoms that are known 
to poorly correlate with the objective clinical findings (4-8). 
For instance, patients with severe DED may present with de-
creased symptoms of discomfort, potentially due to down-
regulation of corneal sensory receptors (7).
Treatment strategies for DED have largely been restricted 
to instillation of various artificial tear formulations, which 
typically provide only short-term relief from DED symptoms 
(9). Despite the fact that topical steroids have shown some 
promise for improving the signs and symptoms of DED, their 
DOI: 10.5301/ejo.5000779 
Efficacy and safety of 0.1% cyclosporine A cationic 
emulsion in the treatment of severe dry eye  
disease: a multicenter randomized trial
andrea leonardi1, Gysbert Van Setten2, Mourad Amrane3, Dahlia Ismail3, Jean-Sebastien Garrigue3, Francisco c. Figueiredo4, 
christophe Baudouin5-7
1 Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua - Italy
2 St. Eriks Eye Hospital, Stockholm - Sweden
3 Santen SAS, Evry - France
4 Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne - UK 
5 Quinze-Vingts National Ophthalmology Hospital, Paris - France 
6 UPMC University, Paris 6, Vision Institute, INSERM UMRS968, CNRS UMR7210, Paris - France 
7 University of Versailles Saint-Quentin en Yvelines, Versailles - France
Introduction
Dry eye is one of the most common ophthalmic diseases, 
with a prevalence ranging from 5% to 35% (1). The term dry 
eye disease (DED) describes a multifactorial disease of the lac-
rimal functional unit that is associated with increased osmo-
larity of the tear film and inflammation of the ocular surface 
(2). Tear hyperosmolarity, resulting from reduced aqueous 
tear flow and/or increased evaporation, drives a vicious cycle 
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ABStRAct
Purpose: The SANSIKA study was conducted to assess the treatment effect of 0.1% cyclosporine A cationic emul-
sion (CsA CE) eye drops on signs and symptoms of patients with severe dry eye disease (DED). 
Methods: This was a multicenter, randomized, double-masked, 2-parallel-arm, 6-month phase III study with a 
6-month open-label treatment safety follow-up. Patients with severe DED with corneal fluorescein staining (CFS)
grade 4 on the modified Oxford scale were randomized to receive once-daily CsA CE (Ikervis®) or its vehicle.
Results: A total of 246 patients were randomized. The proportion of patients achieving ≥2 grades improvement
in CFS and a 30% improvement in symptoms (Ocular Surface Disease Index [OSDI]) by month 6 was 28.6% with
CsA CE vs 23.1% with vehicle (p = 0.326) (primary endpoint). Assessment of corneal damage showed greater
improvement with CsA CE over vehicle in mean adjusted CFS change from baseline to month 6 (-1.764 vs -1.418,
p = 0.037). There was a reduction in ocular surface inflammation assessed by human leukocyte antigen DR ex-
pression in favor of CsA CE at month 6 (p = 0.021). The mean OSDI change from baseline was -13.6 with CsA CE
and -14.1 with vehicle at month 6 (p = 0.858). The main adverse event was instillation site pain (29.2% vs 8.9% in
the CsA CE and vehicle groups, respectively), and it was mostly mild.
conclusions: CsA CE was well-tolerated and effective in improving corneal damage and ocular surface inflam-
mation and confirmed the positive benefit-risk ratio of this new formulation of CsA for the treatment of severe
keratitis in DED.
Keywords: Cationic emulsion, Cyclosporine A, Dry eye disease, Randomized trial, Severe keratitis
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potential benefit is limited by their known iatrogenic ocular 
side effects (such as intraocular hypertension and cataract) 
and are thus not recommended for long-term use (10, 11). A 
therapeutic approach that has received increased attention 
in recent years is inhibition of the inflammatory responses 
associated with DED through the use of anti-inflammatory 
compounds such as cyclosporine A (CsA). Restasis® (Aller-
gan, Inc., Irvine, CA, USA), an anionic oil-in-water emulsion 
incorporating CsA (0.05%), was approved by the US Food and 
Drug Administration in 2003 to treat patients with keratocon-
junctivitis sicca (12). In Europe, there is currently no medici-
nal product that has been approved for treatment of DED; 
however, Santen SAS (Evry, France) has developed a cationic 
emulsion formulation containing 0.1% (1 mg/mL) CsA (CsA 
CE) for the topical treatment of severe forms of immune- 
mediated ocular surface diseases such as DED. This product 
was registered in 2015 in the European Union for the treat-
ment of severe keratitis in adult patients with DED that has 
not improved despite treatment with tear substitutes (13). 
In contrast with Restasis®, CsA CE is a cationic emulsion, the 
instillation of which results in a long-lasting presence of CsA 
in the tear film over the entire surface of the eye (14-16). The 
ocular bioavailability of CsA with the CsA CE formulation is, 
therefore, higher than with previous CsA formulations (16).
Patients with DED with severe keratitis have an increased 
risk of infection, vision loss, and impaired quality of life (1). 
Preclinical and clinical testing of CsA CE has demonstrated a 
positive benefit-risk ratio in this specific patient population. 
A phase III confirmatory trial was conducted in patients with 
severe DED to demonstrate the superiority of CsA CE over its 
vehicle in simultaneously improving signs and symptoms after 
6 months of treatment. In addition, the overall ocular safety 
of CsA CE was assessed after 6 and 12 months of treatment.
Methods
Participants
Patients included in this study were male and female pa-
tients with severe DED aged 18 and older. Eligible patients 
were those having corneal fluorescein staining (CFS) graded 
4 on the modified Oxford scale (from 0 to 5) (17), a Schirmer 
test score ≥2 mm/5 min and <10 mm/5 min (18), and an Ocu-
lar Surface Disease Index (OSDI) score ≥23 (19). 
Study design
This study involved a 6-month, multicenter, randomized, 
double-masked, vehicle-controlled, parallel-group period, fol-
lowed by a 6-month open-label follow-up period. The study 
was conducted in 50 centers in 9 European countries (France, 
Germany, Italy, Spain, Belgium, United Kingdom, Sweden, 
Austria, and the Czech Republic).
Patients initially underwent a 2-week washout period dur-
ing which any ongoing ophthalmic treatments were stopped 
and unpreserved artificial tears (AT) were provided by the 
sponsor for use as frequently as required throughout the 
study (saline solution, Larmabak®, Théa, Clermont-Ferrand, 
France). Patients were randomized to receive one drop once 
daily at bedtime of CsA CE (Ikervis®) unpreserved single-
dose cationic emulsion eyedrops (Santen SAS) or its vehicle 
for 6 months, according to a 2:1 allocation ratio. During the 
open-label phase (the last 6 months), all patients received 
CsA CE. Treatment efficacy and safety were assessed at the 
end of the 6-month randomized period; safety was also as-
sessed at 12 months following the 6-month open-label pe-
riod. Intermediate visits also occurred at months 1, 3, and 9.
All enrolled patients provided written informed con-
sent, and the study was conducted in accordance with the 
principles of Good Clinical Practice and with the ethical 
principles set out in the Declaration of Helsinki. This study 
was registered under the following number in the EudraCT 
database: 2011-000160-97 with the protocol code number 
NVG10E117 (20). 
Efficacy assessments
Efficacy was only determined in the analysis eye, defined 
as the worst eligible eye. 
The same eye (eligible eye) had to fulfill all the appli-
cable aforementioned selection criteria (CFS of 4, Schirmer 
test score ≥2 mm/5 min and <10 mm/5 min, and OSDI score 
≥23). The analysis eye was the eligible eye with the higher 
lissamine green staining score (17) at baseline. If both eyes 
had the same lissamine green staining score, the eye with the 
worse Schirmer test score at baseline was used. If both eyes 
had the same Schirmer test score, the right eye was used. 
To assess the efficacy of CsA CE, both objective (signs) and 
subjective (symptoms) parameters were examined. Objective 
assessments included CFS, Schirmer test (without anesthesia), 
tear break-up time (TBUT) (18), lissamine green conjunctival 
staining using the Van Bijsterveld scale, tear film osmolarity, 
and human leukocyte antigen DR (HLA-DR) expression on 
the conjunctival cell surface by impression cytology (21-23). 
Subjective assessments included OSDI, visual analogue scale 
(VAS) of ocular discomfort, use of concomitant AT, investiga-
tor’s global evaluation of efficacy, and National Eye Institute 
Visual Function Questionnaire (NEI-VQF-25).
Safety assessments
Safety was assessed by best-corrected distance visual acu-
ity (BCDVA) and intraocular pressure (IOP) in both eyes, blood 
sampling for CsA levels, vital signs (blood pressure, pulse rate, 
and respiratory rate), ocular/systemic adverse events (AEs), 
and slit-lamp examination of both eyes. 
Statistical analysis
The primary efficacy endpoint of this study was the com-
bined CFS-OSDI responder rate at month 6. A CFS-OSDI re-
sponder was defined as a subject displaying an improvement 
of ≥2 grades in CFS from baseline and an improvement of 
≥30% in OSDI from baseline. This endpoint was analyzed on 
the full analysis set (FAS) using imputed data with a logistic 
regression model (factors “treatment” and “pooled coun-
try”). The FAS comprised all patients randomized into the 
study who received any amount of the study drug and were 
analyzed according to randomized treatment (intention-
to-treat principle). Missing data were imputed as follows. 
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Patients who discontinued treatment before month 6 were 
considered nonresponders if discontinuation was due to lack 
of efficacy, lack of tolerance, or change in dry eye therapy. 
Patients who discontinued before month 1, or who did not 
discontinue before month 6 but for whom month 1, month 3, 
and month 6 evaluations were missing, were also considered 
as nonresponders. If the patient discontinued before month 
6 due to a reason other than those specified above, a last 
observation carried forward (LOCF) procedure was used (car-
rying forward the month 3 or month 1 evaluation). The LOCF 
was also used if a patient did not discontinue before month 6 
but for whom the evaluation was missing.
Sensitivity analyses were also performed for the primary 
efficacy endpoint using the primary logistic model on the per-
protocol set (PPS), on the FAS using observed data only, and 
on the FAS considering the actual treatment received and 
using a Cochran-Mantel-Haenszel (CMH) test controlling for 
pooled country. The PPS excluded FAS patients with any ma-
jor protocol deviation. 
Further efficacy endpoints were analyzed on the FAS and 
the PPS. The CFS, OSDI, global VAS, and combined CFS-VAS 
responder rates and complete corneal clearing rate were ana-
lyzed using the logistic model described above. Analysis of CFS, 
OSDI, global VAS, and lissamine green score change from base-
line was performed using a repeated-measures analysis of vari-
ance with the following fixed factors: treatment, visit, pooled 
country, and treatment by visit interaction. Schirmer test, TBUT, 
NEI-VQF-25, HLA-DR expression, and tear film osmolarity were 
analyzed using an analysis of covariance model with the fixed 
factors treatment and pooled country, and the corresponding 
baseline data as covariate. A supportive analysis was conducted 
using a CMH test stratified on pooled country. This test was also 
used to analyze the investigator global evaluation of efficacy. 
Sample size calculations were based on the results of a 
previous phase III study performed in patients with moderate 
to severe DED (24). The expected CFS-OSDI responder rates 
at 6 months were 28% and 10% with CsA CE and its vehicle, 
respectively. Setting the risk α at 5% and the power at 90%, 
around 225 evaluable patients were needed (150 in the CsA 
CE group and 75 in the vehicle group) to detect a significant 
difference between groups. Accounting for nonevaluable pa-
tients (approximately 10%), a total of 252 patients were to be 
recruited. 
The safety analysis set was used for reporting safety data; 
this included all randomized patients for whom there was any 
evidence they used study medication and for whom any fol-
low-up data were available. Safety analyses were performed 
using the actual treatment received.
results
Patient demography
Among the 313 patients who were screened, 261 patients 
were randomized to receive treatment. A total of 245 pa-
tients, 154 in the CsA CE group and 91 in the vehicle group, 
were included in the full analysis set. The participant flow 
chart diagram from screening until the completion of the 
study is summarized in Figure 1. Demographic (age and sex) 
and baseline disease characteristics (time since DED diagno-
sis, Sjögren syndrome status) were generally well-balanced 
across the randomized treatment groups (Tab. I). Median use 
of artificial tears during the screening-baseline period was 
relatively similar in both treatment groups (9.2 drops/day/
eye with CsA CE and 10.2 drops/day/eye with vehicle). 
Efficacy results
The results presented below are limited to the double-
masked comparative study period. 
CFS-OSDI responder rate
This analysis shows no statistically significant difference in 
the CFS-OSDI responder rate between treatment groups at 
Fig. 1 - Patient flow during the SANSIKA study. aReason for non-
retention was major breach to good clinical practice. bDuring the 
study, 3 patients were dispensed the incorrect treatment: 1 pa-
tient randomized to 0.1% cyclosporine A cationic emulsion (CsA 
CE) received vehicle and 2 patients randomized to vehicle received 
CsA CE. One patient did not take any study medication and was 
excluded from the full analysis set (FAS). Thus, the FAS consists of 
245 patients: 154 in the CsA CE group and 91 in the vehicle group. 
AE = adverse event; SAF = safety analysis set; TEAE = treatment-
emergent adverse event (defined as an event that started on or 
after the date of the first study drug dose).
Phase III results of 0.1% CsA CE in the treatment of severe dry eye290 
© 2016 The Authors. Published by Wichtig Publishing
taBle i - Baseline demographic characteristics
csa ce (n = 154) Vehicle (n = 91) total (n = 245)
Age, y n = 154 n = 91 n = 245
 Mean (SD) 60.8 (13.5) 62.1 (11.8) 61.3 (12.9)
 Median (min, max) 61.7 (22.9, 87.6) 63.5 (32.7, 86.3) 62.5 (22.9, 87.6)
Sex n = 154 n = 91 n = 245
 Female, n (%) 126 (81.8) 83 (91.2) 209 (85.3)
 Male, n (%) 28 (18.2) 8 (8.8) 36 (14.7)
Sjögren syndrome n = 154 n = 91 n = 245
 Number (%) of patients 58 (37.7) 34 (37.4) 92 (37.6)
Time since diagnosis, y n = 153 n = 91 n = 244
 Mean (SD) 8.8 (7.1) 9.7 (6.7) 9.1 (7.0)
 Median (min, max) 6.2 (0.2, 31.5) 8.7 (0.2, 30.7) 6.8 (0.2, 31.5)
CsA CE = 0.1% cyclosporine A cationic emulsion.
Data represent the full analysis set population.
taBle ii - Responder rates in key efficacy variables after 6 months of randomized treatment with CsA CE or vehicle
csa ce (n = 154) Vehicle (n = 91) p Valuea
Primary endpoint 
  CFS-OSDI response (improvement ≥2 grades [CFS] and 30% [OSDI])
  Responders 44 (28.6) 21 (23.1) 0.326
Secondary endpoints
 CFS response (improvement ≥2 grades)
  Responders 80 (51.9) 41 (45.1) 0.346
 OSDI response (improvement ≥30%)
  Responders 61 (39.6) 36 (39.6) 0.939
 VAS response (improvement ≥30%)
  Responders 48 (31.2) 34 (37.4) 0.302
 CFS-VAS response (improvement ≥2 grades [CFS] and 30% [VAS])
  Responders 35 (22.7) 19 (20.9) 0.744
 Complete corneal clearing (CFS = 0)
  Yes 10 (6.5) 4 (4.4) 0.428
CFS = corneal fluorescein staining graded on a scale from 0 to 5; CsA CE = 0.1% cyclosporine A cationic emulsion; OSDI = Ocular Surface Disease Index question-
naire; VAS = global visual analogue scale assessment of ocular discomfort.
Data represent imputed data on the full analysis set population. Values are n (%).
a p Value for treatment effect in the logistic regression model.
6 months (Tab. II). Based on imputed data and according to 
treatment as randomized, 44 patients (28.6%) with CsA CE 
and 21 patients (23.1%) with vehicle showed a combined im-
provement in CFS (by at least 2 grades) and OSDI (by at least 
30%) at month 6. 
To detect a potential treatment effect on patients show-
ing a marked improvement in CFS over 6 months, a post hoc 
analysis of the primary efficacy endpoint was undertaken that 
increased the threshold for improvement of CFS to 3 grades 
instead of 2 (Fig. 2). When implementing this more stringent 
criterion, the CFS-OSDI responder rate was statistically sig-
nificantly higher in the CsA CE group than the vehicle group 
(p = 0.016) when considering imputed data. From a clinical 
point of view, this difference corresponds to a threefold high-
er likelihood of response with CsA CE treatment than with 
vehicle treatment after 6 months (odds ratio 2.9, 95% con-
fidence interval [CI] 1.3, 7.7). These results were confirmed 
when considering observed data. 
Corneal fluorescein staining
There was a statistically significant improvement in CFS 
score over time (main effect of time: p<0.001) in patients 
receiving either CsA CE or vehicle (Fig. 3). The main effect 
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of treatment over a period of 6 months was in favor of CsA CE 
over vehicle (p = 0.017). The decrease in CFS score from base-
line was greater with CsA CE than with vehicle at each time 
point, reaching statistical significance at month 3 (p = 0.024) 
and month 6 (p = 0.037). Differences between groups in change 
from baseline in CFS score were assessed using the adjusted 
means and observed means. After 6 months of treatment, the 
adjusted mean change in CFS score from baseline was -1.764 
with CsA CE and -1.418 with vehicle, with a difference between 
groups of 0.35. According to the modified Oxford logarithmic 
grading scale, the difference of 0.35 represents a ratio of 1.5 
in the damaged surface area, corresponding to approximately 
50% more punctate dots on the cornea with vehicle compared 
with CsA CE. Per the observed data at 6 months, the mean 
change in CFS score from baseline was -1.81 with CsA CE and 
-1.48 with vehicle, with a difference between groups of 0.33, 
corresponding to approximately 46% more dots on the cornea 
with vehicle compared with CsA CE. 
The likelihood of CFS improvement by at least 3 grades 
within 6 months of treatment (post hoc analysis) was approx-
imately 3 times higher with CsA CE than with vehicle (odds 
ratio 3.3, 95% CI 1.6, 7.0), with 35.6% of the patients reaching 
grade 1 or less in the CsA CE group compared with 14.5% in 
the vehicle group (p = 0.001). 
Impression cytology
The effect of treatment on inflammation at the conjuncti-
val cell surface was determined by using HLA-DR expression as 
a biomarker. The decrease in the level of HLA-DR expression 
from baseline quantified in arbitrary units of fluorescence 
(AUF) was greater with CsA CE than with vehicle (Fig. 4), with 
a statistically significant difference at month 1 (p = 0.019) and 
month 6 (p = 0.021). 
Tear film osmolarity
A trend of improvement in both groups was found with-
out statistical difference between groups. 
Following experts’ recommendations, tear film osmolar-
ity was analyzed post hoc in patients with baseline levels 
>308 mOsm/L (considering the worst value between both 
eyes), a threshold known to be indicative of DED (25). A to-
tal of 55 patients met this criterion, 34 (22.1%) in the CsA 
CE group and 21 (23.1%) in the vehicle group, and the mean 
osmolarity value was similar between these subgroups. 
Fig. 4 - Change in human leukocyte antigen DR (HLA-DR) expression 
over 6 months of randomized treatment with 0.1% cyclosporine A 
cationic emulsion (CsA CE) or vehicle. Data represent median HLA-
DR expression values of the full analysis set population. Compari-
son between groups was performed using an analysis of covariance 
model, after logarithmic transformation.
Fig. 3 - Change in corneal fluorescein staining (CFS) over 6 months 
of randomized treatment with 0.1% cyclosporine A cationic emul-
sion (CsA CE) or vehicle. Data represent mean CFS values ± standard 
error of the full analysis set population. Sample size at baseline and 
months 1, 3, and 6: 154, 149, 140, and 132, respectively, with CsA 
CE, and 91, 88, 89, and 83, respectively, with vehicle. Comparison 
between groups was performed using a repeated-measures analy-
sis of variance.
Fig. 2 - Corneal fluorescein staining (CFS)-Ocular Surface Disease 
Index (OSDI) response rates after 6 months of randomized treat-
ment with 0.1% cyclosporine A cationic emulsion (CsA CE) or vehi-
cle in patients showing a marked improvement in CFS of 3 grades or 
higher and at least 30% improvement in OSDI. Data represent the 
imputed data according to the randomized treatment group and 
the full analysis set population. Comparison between groups was 
performed using a logistic regression model.
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 Although there was an improvement in the worst tear film 
osmolarity over time in both subgroups, the CsA CE subgroup 
showed a significantly greater change from baseline at month 
6 than the vehicle subgroup (p = 0.048), with the mean and 
median values of worst tear film osmolarity in the CsA CE 
subgroup lower than 308 mOsm/L, whereas they remained 
slightly higher than this threshold in the vehicle subgroup 
(Fig. 5 and supplementary Tab. I, available online at www.eur-
j-ophthalmol.com).
Other efficacy analyses
The CFS, OSDI, VAS, and CFS-VAS responder rates and 
complete corneal clearing rate at month 6 are presented in 
Table II. The baseline scores and change from baseline at 
month 6 for OSDI, VAS, and the Schirmer test (without an-
esthesia) are presented in Table III. Schirmer test results are 
also presented in Figure 6A. A general trend of improvement 
in both signs and symptoms was evident in both the CsA CE 
and vehicle treatment groups. Improvements were greater in 
the CsA CE group than in the vehicle group for most variables 
Fig. 5 - Change in worst tear film osmolarity between both eyes in 
patients with >308 mOsm/L at baseline over 6 months of random-
ized treatment with 0.1% cyclosporine A cationic emulsion (CsA CE) 
or vehicle. Data represent mean values ± standard error of a sub-
group of the full analysis set population. Means were adjusted for 
baseline values using an analysis of covariance model with “treat-
ment” and “pooled country” as fixed factors and the baseline data 
as covariate. aOsmolarity ranges taken from Lemp et al (25).
taBle iii - Secondary efficacy assessments: change from baseline after 6 months of randomized treatment with CsA CE or vehicle
csa ce (n = 154) Vehicle (n = 91) p Value
OSDI score
 Baseline n = 154 n = 91
  Mean ± SD 61.4 ± 19.4 58.8 ± 18.4
  Median (min, max) 62.5 (25.0, 100.0) 58.3 (25.0, 100.0)
 Change at month 6 n = 131 n = 82
  Mean ± SD -14.4 ± 21.1 -13.3 ± 18.8
  Adjusted mean (95% CI)a -13.6 (-17.0, -10.0) -14.1 (-18.6, -9.5)
  Median (min, max) -14.6 (-79.2, 45.6) -13.6 (-60.4, 32.5) 0.858
Global VAS assessment (mm)
 Baseline n = 145 n = 85
  Mean ± SD 55.6 ± 20.6 54.5 ± 18.5
  Median (min, max) 55.1 (5.0, 98.0) 52.5 (16.9, 92.5)
 Change at month 6 n = 120 n = 75
  Mean ± SD -13.0 ± 22.7 -10.5 ± 21.6
  Adjusted mean (95% CI)a -12.1 (-16.1, -8.2) -11.2 (-16.3, -6.1)
  Median (min, max) -11.1 (-59.8, 66.6) -10.4 (-59.5, 38.5) 0.766
Schirmer test, mm/5 min
 Screeningb n = 154 n = 91
  Mean ± SD 3.7 ± 2.0 3.9 ± 2.2
  Median (min, max) 3.0 (2.0, 9.0) 3.0 (2.0, 9.0)
 Change at month 6 n = 141 n = 82
  Mean ± SD 2.2 ± 5.7 1.5 ± 4.3
  Median (min, max) 1.0 (-7.0, 32.0) 1.0 (-5.0, 19.0) 0.604c
CI = confidence interval; CsA CE = 0.1% cyclosporine A cationic emulsion; OSDI = Ocular Surface Disease Index questionnaire; VAS = global visual analogue scale 
assessment of ocular discomfort.
Data represent the full analysis set population. Global VAS assessment was measured on a 0%-100% scale. Because the patient was asked to rate each ocular 
symptom by placing a vertical mark on a 100-mm horizontal line, data were recorded in mm rather than % (with 1 mm = 1%).
a Adjusted means were obtained using a repeated-measures analysis of variance model with the following fixed factors: treatment, visit, pooled country, and 
treatment by visit interaction.
b Values obtained at screening are considered baseline values.
c The p value of the nonparametric Cochran-Mantel-Haenszel test was considered instead of the analysis of covariance p value because the distribution of the 
residuals was not normal (as evaluated by the Shapiro-Wilk test).
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without reaching statistical significance. Schirmer test scores 
improved by 72.4% and 58.2% with CsA CE and vehicle, re-
spectively (Fig. 6A), but no significant treatment difference 
was observed. Similarly, the investigator assessment rated 
the patient’s improvement as satisfactory or very satisfactory 
in a slightly higher proportion of patients assigned to CsA CE 
(91 patients, 64.1%) than of patients assigned to vehicle (49 
patients, 57.0%), but this difference did not reach statistical 
significance (p = 0.319). A progressive decrease in the use of 
AT over time was recorded in both treatment groups. Median 
use of AT during the month 3–month 6 period was 4.4 drops/
day/eye with CsA CE (n = 80) and 5.4 drops/day/eye with ve-
hicle (n = 55). 
Lissamine green conjunctival staining, TBUT, and NEI-
VFQ-25 data (Tab. IV) displayed a similar trend to that ob-
served for most of the secondary efficacy variables. A 40.5% 
and 22.2% improvement in TBUT was observed with CsA CE 
and vehicle, respectively, but the difference between treat-
ments was not statistically significant (Fig. 6B). A global trend 
of improvement in both signs and symptoms was found, with 
improvements generally greater (without reaching statistical 
significance) in the CsA CE group than in the vehicle group. 
Safety results
A summary of the treatment-emergent AEs (TEAEs) re-
corded during this study can be found in supplementary 
Table II (available online at www.eur-j-ophthalmol.com). The 
TEAEs considered by the investigator to be treatment-related 
were reported in a higher proportion of patients treated with 
CsA CE (37.0%) than with vehicle (21.1%), and almost all were 
ocular. Most TEAEs were of mild or moderate severity, and 
only one serious TEAE related to treatment was reported (a 
severely reduced visual acuity that occurred in one patient 
treated with vehicle). Instillation site pain, the most frequent-
ly reported treatment-related ocular TEAE, was reported in 
a higher proportion of patients treated with CsA CE (29.2%) 
than with vehicle (8.9%) and was mostly mild (mild: 16.9%, 
moderate: 8.4%, and severe: 3.9% in the CsA CE group ver-
sus 4.4%, 2.2%, and 2.2%, respectively, in the vehicle group). 
Other than instillation site pain, there were no clear trends 
for an increased incidence of any ocular or nonocular TEAE 
(related or not) with either treatment. The treatment-related 
ocular TEAEs reported in at least 1.5% of patients in either 
group were eyelid edema and instillation site erythema (each 
in 3 patients, 1.9%) in the CsA CE group and photophobia (in 3 
patients, 3.3%), eye irritation, and reduced visual acuity (each 
in 2 patients, 2.2%) in the vehicle group. 
Blood sampling revealed that 4 patients treated with CsA 
CE had measurable CsA levels that were below the upper lim-
it of quantification (≤5 ng/mL), which is considered negligible. 
Three patients treated with CsA CE had CsA concentrations 
>5 ng/mL, but these patients were receiving systemic CsA 
treatment (allowed according to the clinical protocol provid-
ed that the treatment remained stable throughout the course 
of the study). There were no remarkable changes in BCDVA, 
IOP, or vital signs. No differences were detected between 
treatments using slit-lamp examination. Safety analyses over 
12 months were performed on the 154 patients who received 
any amount of CsA CE treatment during this time period. Of 
these patients, 114 (74%) completed the 6-month open-label 
phase and were thus exposed to CsA CE for 12 months. The 
safety profile of CsA CE over 12 months was similar to the 
6-month treatment profile (supplementary Tab. II) and did 
not raise any additional safety concerns. 
Discussion
The primary objective of this study was to demonstrate 
the superiority of CsA CE over vehicle in simultaneously im-
proving signs (CFS) and symptoms (OSDI) in patients with 
severe DED, defined as patients with CFS score of 4 on the 
modified Oxford scale, Schirmer test score ≥2 mm/5 min and 
<10 mm/5 min, and OSDI score ≥23, after 6 months of treat-
ment. Although treatment with CsA CE over 6 months was as-
sociated with a significant increase in the CFS-OSDI responder 
rate, a substantial improvement was also observed in patients 
receiving vehicle treatment, and no statistical difference was 
detected between groups. Further efficacy analyses revealed 
a similar trend of improvement in both signs and symptoms of 
DED in patients treated with either CsA CE or vehicle. For in-
stance, the OSDI improvement in both groups after 6 months 
was 14 points on average, which can be considered clinically 
relevant since it is above the minimal clinically important dif-
Fig. 6 - Change in Schirmer test (a) 
and tear film break-up time (B) over 
6 months of randomized treatment 
with 0.1% cyclosporine A cationic 
emulsion (CsA CE) or vehicle. Data 
represent mean values ± standard 
error of the full analysis set popu-
lation. For both tests, comparison 
between groups was performed us-
ing nonparametric Cochran-Mantel-
Haenszel test instead of analysis of 
covariance because the distribution 
of the residuals was not normal (as 
evaluated by the Shapiro-Wilk test). 
CFB = change from baseline.
Phase III results of 0.1% CsA CE in the treatment of severe dry eye294 
© 2016 The Authors. Published by Wichtig Publishing
ference described by Miller and colleagues in 2010, which 
ranges between 7.3 and 13.4 in severe disease (26).
The fact that the superiority of CsA CE over vehicle did 
not reach statistical significance in the primary endpoint, nor 
in most of the other efficacy endpoints, may be explained by 
the ability of the vehicle to improve DED symptoms on its 
own (5, 27). The vehicle, an unpreserved cationic oil-in-wa-
ter nanoemulsion, increases the retention time of nanodro-
plets on the ocular surface by interacting electrostatically 
with the  negatively charged components of the tear film. 
This property improves drug delivery but also enhances film 
hydration, lubrication, and stability (14, 16, 28). Additional-
ly, efficacy endpoints assessing a concomitant improvement 
in both signs and symptoms may have been affected by 
the well-documented weak correlation between signs and 
symptoms in DED (4, 6, 7). The subjective nature of symp-
tom severity and decreased corneal sensation in severe DED 
may explain the difficulty in reaching statistical significance 
in the primary endpoint (6, 29).
Due to the variable and multifactorial nature of the dis-
ease, the required length of treatment may vary between 
individual patients with DED (7, 18), which may also contrib-
ute to the difficulty of efficacy evaluation using the combined 
signs and symptoms endpoint. However, it should be noted 
tABLE IV - Other efficacy assessments: change from baseline after 6 months randomized treatment with CsA CE or vehicle
csa ce (n = 154) Vehicle (n = 91) p Value
Lissamine green staininga
 Baseline n = 134 n = 79
  Mean ± SD 4.5 ± 2.1 4.6 ± 2.2
  Median (min, max) 4.0 (0.0, 9.0) 5.0 (0.0, 9.0)
 Change from baseline at month 6 n = 114 n = 71
  Mean ± SD -1.7 ± 2.1 -1.5 ± 2.2
  Adjusted mean (95% CI)b -1.7 (-2.1, -1.267) -1.4 (-1.9, -0.9) 0.411
  Median (min, max) -2.0 (-6.0, 4.0) -1.0 (-9.0, 5.0)
TBUT
 Baseline n = 154 n = 91
  Mean ± SD 3.3 ± 1.6 3.5 ± 1.7
  Median (min, max) 3.0 (1.0, 7.3) 3.0 (0.0, 8.5)
 Change from baseline at month 6 n = 131 n = 83
  Mean ± SD 0.8 ± 2.1 0.3 ± 1.8 0.298c
  Median (min, max) 0.5 (-5.0, 8.7) 0.0 (-4.5, 7.8)
Tear film osmolarity, mOsm/L
 Baseline n = 57 n = 34
  Mean ± SD 308.1 ± 20.9 305.6 ± 15.5
  Median (min, max) 305.0 (276.0, 366.0) 303.5 (275.0, 339.0)
 Change from baseline at month 6 n = 40 n = 30
  Mean ± SD -3.3 ± 28.3 -5.8 ± 18.0 0.763b
  Median (min, max) -3.0 (-61.0, 118.0) -7.5 (-38.0, 39.0)
NEI-VFQ-25 composite score
 Baseline n = 98 n = 55
  Mean ± SD 71.9 ± 15.74 74.0 ± 13.4
  Median (min, max) 72.9 (11.9, 96.4) 75.8 (43.0, 96.6)
 Change from baseline at month 6 n = 73 n = 46
  Mean ± SD 5.2 ± 8.9 4.8 ± 9.9
  Adjusted mean (95% CI)d 4.1 (1.9, 6.2) 4.0 (1.3, 6.6) 0.945
  Median (min, max) 4.7 (-15.7, 32.3) 5.0 (-21.2, 24.7)
CI = confidence interval; CsA CE = 0.1% cyclosporine A cationic emulsion; NEI-VFQ-25 = National Eye Institute Visual Function Questionnaire; TBUT = tear break-
up time.
Data represent the full analysis set population.
a Data presented do not include data from patients for whom investigators were not able to perform the lissamine green examination correctly.
b Adjusted means were obtained using a repeated-measures analysis of variance model with the following fixed factors: treatment, visit, pooled country, and 
treatment by visit interaction.
c The p value of the nonparametric Cochran-Mantel-Haenszel test was considered instead of the analysis of covariance (ANCOVA) p value because the distribu-
tion of the residuals was not normal (as evaluated by the Shapiro-Wilk test).
d Means were adjusted for baseline values using an ANCOVA model with the fixed factors treatment and pooled country and the baseline data as covariate.
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that preclinical evaluations of CsA CE demonstrated maximal 
corneal and conjunctival CsA penetration at the concentra-
tion and posology used in this study (14).
There was a clear trend of greater improvement in patients 
receiving once-daily CsA CE compared with vehicle in most 
efficacy assessments. The superiority of CsA CE over vehicle 
reached statistical significance with regard to improvement in 
the quality of the corneal surface (CFS score) and the reduc-
tion of ocular surface inflammation (HLA-DR expression). The 
benefit of CsA CE treatment over vehicle in reducing corneal 
staining (CFS) over time was evident as early as month 3, and 
the difference between groups at month 6 of 0.35 represents, 
on average, 50% more corneal staining in the vehicle group 
compared with the CsA CE group, which is considered clinically 
relevant. A significant decrease in HLA-DR expression (quanti-
fied in AUF) was evident in the CsA CE group even after only 1 
month of treatment. Conversely, vehicle treatment had almost 
no effect on this inflammatory biomarker over 6 months. The 
effect of CsA CE in this respect is most likely associated with the 
well-established anti-inflammatory properties of CsA (21, 23, 
30-35). In this study, HLA-DR expression was also assessed us-
ing percentage of HLA-DR+ cells. The results showed no differ-
ence between groups due to the fact that this analysis cannot 
discriminate a population with a high fluorescence expression 
from another with a low fluorescence.
Post hoc data analyses provided further support for the su-
periority of CsA CE over vehicle in the treatment of DED. When 
considering patients showing a marked improvement in CFS of 
3 grades instead of 2 (as was specified in the primary efficacy 
endpoint), there was a statistically significant difference in the 
CFS-OSDI responder rate between treatment groups. Addition-
ally, when considering tear film osmolarity in the subgroup of 
patients who had a baseline value greater than the commonly 
accepted threshold indicative of DED (25), the CsA CE subgroup 
showed a significantly greater improvement than the vehicle 
subgroup. 
The CsA CE was generally found to be well-tolerated in 
most patients, with no systemic findings that could suggest 
systemic absorption of cyclosporine. Apart from brief instil-
lation site pain, which was more common in patients treated 
with CsA CE, there were no clear trends for an increased in-
cidence of any ocular TEAE with either treatment. Further-
more, no detrimental effects on visual acuity, IOP, or vital 
signs were observed. 
In conclusion, in the present study, CsA CE (Ikervis®)—a 
novel formulation of unpreserved single-dose cationic emulsion 
of cyclosporine 0.1%—was well-tolerated and effective in im-
proving corneal surface damage and ocular surface inflamma-
tion. These benefits were achieved with a single daily instilla-
tion, which, compared with other DED treatments that require 
multiple instillations for efficacy, may reduce patient burden 
and improve quality of life (1). This study confirms the positive 
benefit-risk ratio of once-daily administration of Ikervis® in the 
treatment of severe keratitis in patients with severe DED. 
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ONLINE-ONLY SUPPLEMENTARY MATERIAL  
Supplementary Table I. Change in worst tear film osmolarity between both eyes 
after 6 months randomised treatment with CsA CE or vehicle in patients with 
baseline values >308 mOsms/L 
 
 
CsA CE 
n=154 
Vehicle 
n=91 
 
p value 
Tear film osmolarity (mOsms/L) 
Baseline n=34 n=21  
MeanSD 331.020.2 321.510.5  
Median (min, max) 327.5 (309.0, 385.0) 319.0 (310.0, 346.0)  
Change at Month 6 n=25 n=17  
MeanSD –25.218.5 –9.517.5  
Adjusted mean (95% 
CI)a 
–26.7 (–35.0, –18.3) –16.7(–25.0, –8.4) p=0.048 
Median (min, max) –24.0 (–72.0, 0.0) –9.0 (–38.0, 19.0)  
Data represent a subgroup of the FAS population. 
CsA CE: 0.1% ciclosporin A cationic emulsion; SD: standard deviation; 95% CI: 95% confidence 
interval.  
a Means were adjusted for baseline values using an analysis of covariance (ANCOVA) model 
with the fixed factors: “treatment” and “pooled country” and the baseline data as covariate. 
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Supplementary Table II. Summary of adverse events recorded during the study 
 
TEAEs  
CsA CE 
6 months 
n=154 
Vehicle  
6 months 
n=90 
CsA CE 
12 months  
n=154 
n (%) 
patients 
n 
events 
n (%) 
patients 
n 
events 
n (%) 
patients 
n 
events 
Any TEAE 88 (57.1) 175 42 (46.7) 88 113 (73.4) 275 
Any treatment-related TEAE 57 (37.0) 95 19 (21.1) 30 70 (45.5) 128 
Any ocular TEAE 66 (42.9) 112 27 (30.0) 44 86 (55.8) 160 
Any treatment-related ocular 
TEAEs 
57 (37.0) 90 18 (20.0) 29 70 (45.5) 118 
Any TEAE leading to 
discontinuation
a
 
21 (13.6) 34 9 (10.0) 11 31 (20.1) 51 
Any ocular TEAE leading to 
discontinuation 
18 (11.7) 29 6 (6.7) 8 27 (17.5) 40 
Any severe ocular TEAE 9 (5.8) 16 5 (5.6) 8 11 (7.1) 19 
Any SAE
b
 6 (3.9)
b
 6
b
 6 (6.7) 6 14 (9.1) 14 
Any treatment-related SAEs 0 (0.0) 0 1 (1.1) 1 0 (0.0) 0 
Any ocular SAE 0 (0.0) 0 1 (1.1) 1 0 (0.0) 0 
Deaths  0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 
Data represent patients who received any amount of treatment over the specified time period. 
CsA CE: 0.1% ciclosporin A cationic emulsion; TEAE: treatment-emergent adverse event; SAE: 
serious adverse event. 
If a patient had multiple occurrences of an event, the patient was counted only once in the 
corresponding patient count. 
a This category is about TEAEs that led to permanent discontinuation of treatment. All patients 
who stopped treatment were also discontinued from the study, except one patient who 
continued the study and completed the 6-month randomised treatment phase. 
b There was 1 SAE that started during the double-masked period (up to Month 6) but its 
seriousness (i.e. event requiring hospitalization) was known by the investigators after the 
double-masked period  database lock.  
 
